Trial Profile
A Phase 1, Randomized, Two-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 986360 (Primary)
- Indications Hepatic fibrosis; Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 14 Oct 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 29 Apr 2014 New trial record